Atlas Wealth LLC Grows Stock Position in GE Vernova Inc. $GEV
π Atlas Wealth LLC grew its GE Vernova holdings by 13,186.5% in Q1, adding 76,218 shares to a total holding of 76,796 shares valued at $67.0 million.
π The company reported $17.44 EPS for the quarter, significantly beating analyst estimates of $1.95 by $15.49.
π° Revenue reached $9.34 billion, a 17.0% increase year-over-year that surpassed the consensus estimate of $9.19 billion.
π Morgan Stanley raised its price target to $960.00 and maintained an 'overweight' rating on GE Vernova shares.
π Royal Bank of Canada boosted its price objective to $1,195.00 with an 'outperform' rating in a recent report.
π Jefferies Financial Group lowered its target price to $1,210.00 while maintaining a 'buy' rating for the stock.
π BNP Paribas Exane downgraded GE Vernova from 'outperform' to 'neutral' with a $1,190.00 price target.
πΈ The company declared a quarterly dividend of $0.50 per share, paid on July 14th to stockholders of record as of June 16th.
π GE Vernova achieved a return on equity of 43.97% and a net margin of 23.81% in the most recent quarter.
π The average analyst price target for GE Vernova is currently $1,089.88 according to MarketBeat data.
- Atlas Wealth LLC increased its position by 13,186.5% in Q1, signaling strong institutional confidence and making the stock its third-largest holding.
- The company reported $17.44 EPS, which was a massive beat of $15.49 above analyst consensus estimates.
- Revenue of $9.34 billion exceeded expectations of $9.19 billion and grew 17.0% year-over-year.
- Morgan Stanley raised its price target to $960.00 and reaffirmed an 'overweight' rating on the stock.
- Royal Bank of Canada increased its price objective to $1,195.00 and issued an 'outperform' rating.
- The company achieved a robust return on equity of 43.97% and a net margin of 23.81%.
- Jefferies Financial Group lowered its price target from $1,350.00 to $1,210.00 despite maintaining a 'buy' rating.
- BNP Paribas Exane downgraded the stock from 'outperform' to 'neutral' with a target of $1,190.00.
- Zacks Research lowered its rating from 'strong-buy' to 'hold' in a recent note.
- The current average analyst price target of $1,089.88 is below the stock's 52-week high of $1,195.94.